-transparent.png){kind=logo}
OBJECTIVE Metabolic activity of transformed human liver (Hep G2) cells and primary rat hepatocytes were compared during in vitro application of a gel entrapment bioartificial liver. BACKGROUND Clinical trials of bioartificial liver devices containing either transformed liver cells or primary hepatocytes have been initiated. A study comparing transformed liver cells and primary hepatocytes in a bioartificial liver under similar conditions has not been reported previously. METHODS Gel entrapment bioartificial liver devices were inoculated with 100 million cells, Hep G2 cell line (n = 4), or rat hepatocytes (n = 16), and studied for up to 60 days of in vitro cultivation. RESULTS Hep G2 cells grew to confluence within the gel entrapment configuration with a doubling time of 20 +/- 3 hours. Rat hepatocytes significantly outperformed Hep G2 cells at confluence in all categories of biotransformation, including ureagenesis (3.5 +/- 0.7 vs. 0.3 +/- 0.1 mumol/hr, p < 0.05), glucuronidation (630 +/- 75 vs. 21 +/- 2 nmol/hr, p < 0.005), sulfation (59 +/- 13 vs. 5 +/- 2 nmol/hr, p < 0.05), and oxidation (233 +/- 38 vs. < 1 nmol/hr, p < 0.005). At the conclusion of one experiment, Hep G2 cells were found in the extracapillary compartment of the bioartificial liver, analogous to the patient's compartment during clinical application. CONCLUSIONS Primary rat hepatocytes were superior to the Hep G2 cell line as the source of hepatic function in a bioartificial liver and avoided the potential risk of tumor transmigration from the bioartificial liver into the patient's circulation.
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
January 1986,
ASAIO transactions,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
January 2007,
Hepato-gastroenterology,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
October 1998,
Artificial organs,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
June 2007,
Archives of pharmacal research,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
November 1989,
Hepatology (Baltimore, Md.),
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
December 1989,
Journal of nutritional science and vitaminology,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
April 1989,
Nihon Geka Gakkai zasshi,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
August 1996,
British journal of pharmacology,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
July 1990,
Biochemical and biophysical research communications,
S L Nyberg, and
R P Remmel, and
H J Mann, and
M V Peshwa, and
W S Hu, and
F B Cerra
March 1993,
In vitro cellular & developmental biology : journal of the Tissue Culture Association,
